Elevate-Derm Summer 2025: Full Conference Recap

New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.

Day 3 of EADV 2026 featured long-term psoriasis data, advances in hidradenitis suppurativa, evolving approaches to atopic dermatitis, and late-breaking research.

Seven presentations will highlight phase 3 maintenance and induction findings, 3-year phase 2 data, and preclinical research evaluating obefazimod in ulcerative colitis.

Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin.

Christophe Piketty, MD, PhD, discussed 3-year findings from the ARCADIA long-term extension study and the implications of targeting IL-31 in atopic dermatitis.

In TRANQUILLO 2, 21.86% of patients taking ritlecitinib 100 mg achieved F-VASI75 at week 52 vs 2.40% with placebo, according to data presented at EADV 2026.

At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.

Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.